Ovarian cancer cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Huda A. Karman, M.D.

Overview

The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient. Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression.

The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient.^[1]
Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression.^[2]

↑ Martín-Cameá, María; Delgado-Sánchez, Elsa; Piñera, Antonio; Diestro, Maria Dolores; De Santiago, Javier; Zapardiel, Ignacio (2016). “The role of surgery in advanced epithelial ovarian cancer”. ecancermedicalscience. 10. doi:10.3332/ecancer.2016.666. ISSN 1754-6605.
↑ Duong, M.; Wright, E.; Martin-Nunez, I.; Yin, L.; Ghatage, P.; Fung-Kee-Fung, M. (2016). “The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada”. Current Oncology. 23 (5): 461. doi:10.3747/co.23.3139. ISSN 1718-7729.